

Supplementary Table 1

patient no.	gender	age	diagnosis	postive rate (%)							site density								
				CD32	CD19	CD20	CD22	CD23	ROR1	FcγR	CD32B	CD32	CD19	CD20	CD22	CD23	ROR1	FcγR	CD32B
1	female	55	CLL	100	99.8	51	50.1	47.5	77.3	69.9		43349	18155	3728	3465	3597	3878	4516	
2	male	54	CLL	100	97.7	47.8	48.1	97.6	91.5	99		50618	11426	3123	2937	6967	4388	7168	
3	female	52	CLL	100	100	99.9	100	0.14	0.019	94.6		28075	20581	24233	16446	41	11	4475	
4	male	61	CLL	100	89.9	6.41	6.43	1.73	94.4	13.8		29271	6348	870	1092	400	4295	1762	
5	female	64	CLL	100	97.5	10.1	32.6	0.036	91.9	40.3		40099	10000	1086	2341	120	4228	2624	
6	male	53	CLL	100	94	99.9	100	22.7				60984	38143	18922	27768	2133			
7	male	70	CLL	100	100	22	91.5	39.7				21833	19359	2250	8576	3630			
8	male	55	CLL	100	100	34.4	93.5	51.6				29775	20917	2779	9114	4463			
9	female	72	CLL	100	100	26.2	83	26.7				46353	21571	2577	6074	2562			
10	male	68	CLL	100	99.8	2.09	24.3	3.36				31439	18145	942	3611	1076			
11	male	70	CLL	100	99.7	17.5	67.9	27.3	97.8	92.1		36984	15099	1566	3691	1924	5250	5754	
12	male	73	CLL	100	99.9	100	100	4.22	0.088	98.8		63251	19148	51037	30012	897	112	8536	
13	male	49	CLL/SLL	100	100	51.3	54	34.1	80.4	91.6		33951	21065	3957	3764	2778	4438	6482	
14	male	71	CLL	100	99.8	100	100	0.21	20.9	84		26585	24203	44007	25007	0	2097	4150	
15	male	86	CLL	100	99.9	94.3	99.6	4.59	99	98.9		32045	23165	29322	8672	594	7009	7328	
16	male	74	CLL	100	99.9	84.9	55.3	82.5	95.1	97.6		48302	20528	6175	3527	6286	5535	6320	
17	male	61	CLL	100	100	69	96.8	26.1	90.1	97.1		50715	28140	4643	7249	2057	4955	6156	
18	male	55	CLL	100	99.9	91.8	94.5	86.8	19.8	88.2		32736	19670	8807	9272	8225	1941	4517	
19	male	75	CLL	100	99.8	57.3	7.92	26.7	91.8	95.5		42273	14021	4260	805	2203	5298	6182	
20	male	53	CLL (Richer)	100	99.8	24	23.9	3.5	78.3	21.4		25342	10525	2028	2216	617	3944	2305	
21	male	64	CLL	100	99.8	46.8	29.6	56.3	82.6	83.4		22897	16210	3214	2347	3944	5369	4475	
22	male	57	CLL	100	98.9	100	99.6	0.24	0.14	61.2		50372	17970	21563	13699	344	963	3744	
23	male	68	CLL	100	100				91.1	97.5		39893	19953				4239	10214	
24	male	72	CLL/SLL	100	99.9				48.4	98.9		66448	16667				2731	6963	
25	female	63	CLL	100	99.9				64.3	99.3		25203	16816				3090	6915	
26	male	68	CLL	100	99.8				94.4	76.2		57120	13762				4584	3482	
27	male	65	CLL	100	98.5				95	99.6		36313	26893				5678	8072	
28	female	76	CLL	100	100	71.2						32126	23201	6681					
29	male	68	CLL	100	99.1	10.5						23696	12302	1408					
30	male	73	CLL	99.9	87.7	98.6						56789	9930	24960					
31	male	71	CLL	100	100	59.4						25723	22776	3392					
32	male	58	CLL	100	100							29386	22801						
33	female	53	CLL	100	100							40241	23428						
34	male	66	CLL	100	94.8							23515	8926						
35	male	54	CLL	100	100							31843	24630						
36	male	73	CLL	100	98.7							38959	17722						
37	male	69	CLL	100	100							66814	24880						
38	male	58	CLL	100	99.4							57046	23669						
39	male	49	CLL	100	99							55393	22990						
40	male	72	CLL	100	91.8							54821	8577						
41	female	49	CLL	100	97.4							44686	15263						
42	female	61	CLL	100	99	98	97.5	0.31			100	36551	18466	22131	13289	239		31848	
43	male	62	CLL	100	97.5	91.1	94	0			100	40439	14002	11764	14578	16		42497	
44	male	68	CLL	100	99.9	97.1	99.5	3.67			100	45710	35179	49019	17262	486		52733	
45	female	65	CLL	100	99.9	100	100	0			100	48335	23228	28253	35279	16		55137	
46	male	57	CLL	100	100	97	96.4	0			100	51015	32777	17074	17310	1		48428	
47	male	64	CLL	100	99.8	38.8	70.6	68.2			98.8	24438	16066	3689	6087	9161		23795	
48	male	51	CLL	100	96.4	0.21	58.7	0.67			99.8	13677	8483	224	4169	296		16247	

Markers' expression defined by flow cytometry using FMO and isotype controls. All these patients matched the diagnostic criteria for CLL according to NCCN clinical practice guidelines in oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, version 1.2020.